Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
77
datasets available to search
ShareScore release 0.9.0
Dataset results
77 results for “MMR”
Single amyloid PET scan on the Siemens Biograph mMR
<p>In version 1.0, this zipped dataset consists of a full dynamic list-mode PET data of 60 minutes of acquisition, using an amyloid tracer, florbetapir, provided by Eli Lilly. Also, the dataset includes normalisation files and the UTE mu-map, all needed for an independent image reconstruction using NiftyPET.</p> <p>In version 2.0, the dataset is enriched by MR T1w and N4 bias corrected image, the parcellated T1w image into 140+ brain regions, the pseudo-CT image (based on T1w image) for more accurate attenuation correction, and the <testing_reference> folder with all images used for testing the installation or a new version of NiftyPET. </p> <p>https://github.com/pjmark/NiftyPET</p> <p>https://link.springer.com/article/10.1007/s12021-017-9352-y</p>
NEMA image quality phantom acquisition on the Siemens mMR scanner
<p>NEMA image quality (IQ) phantom data acquired on the Siemens Biograph mMR PET/MR scanner. 60 minutes of PET data were acquired. The list mode acquisition and associated files required for reconstruction are provided.</p>
Looking in the medicine cabinet: methods for using real-world data to assess the impact of measles, mumps and rubella (MMR) and recombinant adjuvanted varicella-zoster vaccines on coronavirus disease 2019 (COVID-19) prevention and case fatality
<p>Supplementary File S1. 20210712_vx_off_target_pubdraft_S1 (Tables, Graphs and scripts associated with publication)</p> <p>Data file 1. Basic_Analysis.R (descriptive analysis script in R, for use with cleaned data files 3, 4 and 6)<br> Data file 2. Cleaning (Script demonstrating how Cerner data was cleaned upon download)<br> Data file 3. COVID_all_cleaned (CSV file with all COVID+ subjects in Cerner institutions)<br> Data file 4. COVID_mmr_data_cleaned (CSV file with COVID+ patients between 25-64 years old, including institution id, age category, gender, whether patient is in emergency department or inpatient, flu vaccine history, MMR vaccine history and mortality outcomes)<br> Data file 5. COVID_mmr_data_matched (CSV file matching MMR vaccine-exposed cases to controls based on propensity scores)<br> Data file 6. COVID_zoster_data_cleaned (CSV file with COVID+ patients above 50 years old, including institution id, age category, gender, whether patient is in emergency department or inpatient, flu vaccine history, zoster vaccine history and mortality outcomes)<br> Data file 7. COVID_zoster_data_matched (CSV file matching zoster vaccine-exposed cases to controls based on propensity scores)<br> Data file 8. General_25_64_data_cleaned (CSV file, all patients in Cerner institutions between 25 – 64 years old, including institution id, age category, gender, whether patient is in emergency department or inpatient, flu vaccine history, MMR vaccine history, SARS-CoV-2 infection and COVID-19 mortality outcomes ).<br> Data file 9. General_over50_data_cleaned (CSV file, all patients in Cerner institutions above 50 years old, including institution id, age category, gender, whether patient is in emergency department or inpatient, flu vaccine history, zoster vaccine history, SARS-CoV-2 infection and COVID-19 mortality outcomes).<br> Data file 10. Included_tenants (CSV file, institution IDs whose contributed cases comprise at least 0.5% of the aggregate sample size).<br> Data file 11. MMR_ps (R script to run for MMR-related files analysis)<br> Data file 12. Zoster_ps (R script to run for zoster-related files analysis)</p>
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months
ClinicalTrials.gov study NCT02184572. IPD Sharing: Not stated. Countries: 5. Publications: 1.
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
ClinicalTrials.gov study NCT01621802. IPD Sharing: YES. Countries: 3. Publications: 1.
Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years
ClinicalTrials.gov study NCT00871117. IPD Sharing: YES. Countries: 1. Publications: 1.
Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age
ClinicalTrials.gov study NCT00861744. IPD Sharing: YES. Countries: 2. Publications: 2.
A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts
ClinicalTrials.gov study NCT04428359. IPD Sharing: NO. Countries: 1. Publications: 32.
Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer
ClinicalTrials.gov study NCT02981524. IPD Sharing: NO. Countries: 1. Publications: 1.
Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
ClinicalTrials.gov study NCT03519412. IPD Sharing: Not stated. Countries: 1. Publications: 6.
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of
ClinicalTrials.gov study NCT01702428. IPD Sharing: YES. Countries: 6. Publications: 1.
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
ClinicalTrials.gov study NCT01681992. IPD Sharing: Not stated. Countries: 7. Publications: 1.
Analysis of measles-mumps-rubella (MMR) titers of recovered COVID-19 patients
<p>The measles-mumps-rubella (MMR) vaccine has been theorized to provide protection against COVID-19. Our aim was to determine whether any MMR IgG titers are inversely correlated with severity in recovered COVID-19 patients previously vaccinated with MMR II. We divided 80 subjects into two groups, comparing MMR titers to recent COVID-19 severity. The MMR II group consisted of 50 subjects who would primarily have MMR antibodies from the MMR II vaccine, and a comparison group of 30 subjects who would primarily have MMR antibodies from sources other than MMR II, including prior measles, mumps, and/or rubella illnesses. There was a significant inverse correlation (<i>r<sub>s</sub></i> = -0.71, <i>P</i> < .001) between mumps titers and COVID-19 severity within the MMR II group. There were no correlations between mumps titers and severity in the comparison group, between mumps titers and age in the MMRII group, or between severity and measles or rubella titers in either group. Within the MMR II group: mumps titers of 134 to 300 AU/ml (n=8) were only found in those who were functionally immune or asymptomatic; all with mild symptoms had mumps titers below 134 AU/ml (n=17); all with moderate symptoms had mumps titers below 75 AU/ml (n=11); all who had been hospitalized and required oxygen had mumps titers below 32 AU/ml (n=5). Our results demonstrate that there is a significant inverse correlation between mumps titers from MMR II and COVID-19 severity.</p>
Response to Immunotherapy in MMR-deficient Localized Colon Cancer
ClinicalTrials.gov study NCT05662527. IPD Sharing: YES. Countries: 1. Publications: 2.
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
ClinicalTrials.gov study NCT04117087. IPD Sharing: NO. Countries: 1. Publications: 0.
First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-pro
ClinicalTrials.gov study NCT06502743. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
ClinicalTrials.gov study NCT03712943. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines
ClinicalTrials.gov study NCT01307436. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children
ClinicalTrials.gov study NCT02253407. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)
ClinicalTrials.gov study NCT00432523. IPD Sharing: Not stated. Countries: 2. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.